Navigation Links
Mpex Pharmaceuticals, Inc. to be Acquired by Axcan
Date:4/14/2011

SAN DIEGO, April 14, 2011 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. announced today that Axcan and Mpex have entered into agreements pursuant to which Axcan will acquire all of the outstanding shares of Mpex and its lead product candidate, Aeroquin™.  A proprietary aerosol formulation of levofloxacin, Aeroquin is currently in Phase 3 clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis (CF).  

All assets not associated with Aeroquin™, including financial and human resources, will be spun out of Mpex and into a newly formed company.  The new company will remain in San Diego and the former personnel of Mpex will continue to lead the Aeroquin clinical development program in collaboration with Axcan.  

Specific financial terms for this transaction were not disclosed but include an upfront payment and a series of payments contingent on regulatory and commercial success.  The full acquisition, which is contingent upon customary closing conditions, is expected to close in the second half of 2011.

"Axcan has a long history of developing and commercializing pharmaceutical products for the cystic fibrosis community, as evidenced most recently by ZENPEP®," stated Daniel Burgess, President and CEO of Mpex.   "We look forward to working with the dedicated team at Axcan to help bring this potentially important new treatment option to patients with CF."

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. Mpex's most advanced product candidate, Aeroquin™ (MP- 376), is a proprietary aerosol formulation of levofloxacin that is currently in Phase 3 clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.  The Company has a number of additional antibiotic programs designed to address antibiotic resistance in gram negative organisms, including a collaboration with GlaxoSmithKline focused on developing drug candidates utilizing Mpex's efflux pump inhibitor (EPI) technology. Company website: www.mpexpharma.com.

About Axcan 

Axcan, with the recent acquisition of Eurand Pharmaceuticals Inc., is a privately held, leading global specialty pharmaceutical company with clinical, manufacturing and commercial operations in the United States, the European Union and Canada. Axcan develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies used in the treatment of a variety of gastrointestinal and other disorders, including cystic fibrosis. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.Axcan.com.


'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
2. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
3. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
4. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
5. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
6. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
7. Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals, Inc.
8. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
9. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 2017 According to a new market research ... Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User ... MarketsandMarkets, the market is expected to reach USD 330.6 Million by ... 3.7% from 2016 to 2021. Continue ... ...
(Date:2/17/2017)... Feb. 17, 2017 Theravance Biopharma, Inc. ... the "Company") today announced the presentation of positive ... orally administered pan-Janus kinase (JAK) inhibitor designed to ... Congress of the European Crohn,s and Colitis Organization ... further data from its completed Phase 1 study ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
Breaking Medicine Technology:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... and check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of ... No. 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex ...
(Date:2/20/2017)... ... February 20, 2017 , ... Best Doctors® and IBM ... benefit for companies that want to help members of their workforce battling cancer. ... access to Watson’s suite of oncology offerings for insights on cancer treatment options, ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for ... joint event at Chuck E. Cheese’s locations throughout New England, New York and New ... opportunity to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. ...
(Date:2/19/2017)... Van Wert, OH (PRWEB) , ... February 19, 2017 , ... ... known as The JEMS Conference & Exposition, the event will take place February 23-25, ... Utah. Braun Industries will be in Booth #909 with three new ambulances ...
(Date:2/18/2017)... Church, VA (PRWEB) , ... ... ... Culture of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends ...
Breaking Medicine News(10 mins):